drugset / Trial / NCT02504268

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268

Phase 3 Completed 994 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.

Timeline

Start
2015-09-03
Primary completion
2017-01-16
Completion
2020-03-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 125 mg Subcutaneous
Background Methotrexate Small molecule 15 mg Oral

Indications